#### Pending Claims

A complete list of all claims under examination is set out below. Please amend claims 11, 16, 22, 23, 25, 26, 28, 31, 32, 50, 51 and 52 as indicated below. Claims 1-10, 17, 19-21, 34, and 36-49 are cancelled.

#### 1 - 10. (cancelled).

11. (currently amended) The compound of claim 50 having of the formula:

$$R_{11}$$
 $R_{20}$ 
 $R_{11}$ 
 $R_{20}$ 
 $R$ 

wherein

$$\begin{split} R_{11} &\text{ is } C_5\text{-}C_{18} &\text{ alkvyl, } C_5\text{-}C_{18} &\text{ alkenyl, } C_5\text{-}C_{18} &\text{ alkvnyl, } C_5\text{-}C_{18} &\text{ alkoxy, } C_1\text{-}C_{10} &\text{ alkyl}(C_5\text{-}C_6 \\ &\text{aryl})R_{20}, C_1\text{-}C_{10} &\text{ alkyl}(C_5\text{-}C_6 &\text{ cycloalkyl})R_{20}, C_1\text{-}C_{10} \\ &\text{ alkoxy}(C_5\text{-}C_6 &\text{ aryl})R_{20}, C_1\text{-}C_{10} &\text{ alkoxy}(C_5\text{-}C_6 &\text{ beteroaryl})R_{20} \\ &\text{ or } C_1\text{-}C_{10} &\text{ alkoxy}(C_5\text{-}C_6 &\text{ cycloalkyl})R_{20}; \end{split}$$

wherein R20 is H or C1-C10 alkyl;

p and q are integers independently ranging from 1 to 10;

 $R_{29} \ is \ H, \ halo, \ C_1 - C_{12} \ alkyl, \ C_{\underline{24}} - C_{12} \ alkenyl, \ C_{\underline{24}} - C_{12} \ alkynyl, \ or \ C_1 - C_{12} \ alkoxy,;$ 

R7 and R8 are independently O, S, CR26, CHR26, NR26, or N;

wherein R26 is H, F or C1-C4 alkyl;

R25 is CH;

R<sub>3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)OH, or (C<sub>1</sub>-C<sub>4</sub> alkyl)NH<sub>2</sub>;

R<sub>15</sub> is

$$R_{12} = R_{30}$$

wherein R<sub>12</sub> is O or S;

X is O, S, CH<sub>2</sub>, CHOH, CHF, CF<sub>2</sub>, or 
$$-C^-$$
;

R<sub>30</sub> and R<sub>31</sub> are independently C<sub>1</sub>-C<sub>2</sub> alkoxy,

 $R_{23}$  is H, F, OH,  $C_1$ - $C_4$  alkyl,  $CO_2$ H or  $(C_1$ - $C_4$  alkyl)OH;

R24 is H, F, C1-C4 alkyl or PO3H2; or

 $R_{23}$  together with  $R_{24}$  and the carbon to which they are attached form a carbonyl group; and

y and m are integers independently ranging from 0 to 4; or a pharmaceutically acceptable salt or tautomer thereof.

12. (previously presented) The compound of claim 11 wherein

m is 0;

v is 0 or 1:

R23 and R24 are independently H or F.

13. (previously presented) The compound of claim 11 wherein R3 is C1-C3 alkyl or (C1-C4 alkyl)OH; and

R<sub>8</sub> is CH.

(previously presented) The compound of claim 12 wherein 14.

R11 is C5-C18 alkyl, C5-C18 alkenyl, C5-C18 alkynyl, or C5-C18 alkoxy and

R20 is H, halo or C1-C12 alkyl; or

a pharmaceutically acceptable salt or tautomer thereof.

15. (previously presented) The compound of claim 12 wherein

v is 0; and

R<sub>15</sub> is represented by the structure

$$-x-P$$
 $R_{30}$ 

wherein X is CH2, CHOH, CHF, CF2, or -C

16. (currently amended) The compound of claim 50 of 12 having the formula:

$$R_{11}$$

$$R$$

wherein  $R_{11}$  is  $C_5$ - $C_{18}$  alkyl or  $C_5$ - $C_{18}$  alkenyl; and  $R_8$  is N, CH or S;

or a pharmaceutically acceptable salt or tautomer thereof.

# 17. (cancelled)

18. (previously presented) The compound of claim 16 wherein  $R_{11}$  is  $C_5\text{-}C_9$  alkyl;  $R_{15}$  is

$$-X-P < R_{30} R_{31}$$

wherein X is O, CH2 or CHF;

 $R_{30}$  and  $R_{31}$  are independently

USSN: 10/578,216 Group Art Unit: 1626

Docket No.: 198P00944USWO

and R3 is CH3.

- 19. 21. (cancelled)
- 22. (currently amended) The compound of claim 51 having of the formula:

(currently amended) The compound of claim 22 wherein R<sub>3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl or (C<sub>1</sub>-C<sub>4</sub> alkyl)OH;

R<sub>8</sub> is O, S, CR<sub>26</sub> or N;

R23 is and R26 are independently H or F; and

R<sub>15</sub> is represented by the structure

$$-x-P = \begin{cases} R_{30} \\ R_{31} \end{cases}$$
 wherein X is O, CH<sub>2</sub>, CHOH, CHF, CF<sub>2</sub> or  $-C$ 

- 24. (previously presented) The compound of claim 53 wherein X is O.
- 25. (currently amended) The compound of  $\frac{\text{claim } 24}{\text{claim } 53}$  wherein X is CH<sub>2</sub>, CHF or CF<sub>2</sub>.

 (currently amended) The compound of elaim-24 claim 53 wherein R<sub>30</sub> and R<sub>31</sub> are the same and are

$$0 \longrightarrow 0 \longrightarrow 0 \longrightarrow 0 \longrightarrow 0$$

$$0 \longrightarrow$$

- 27. (original) The compound of claim 25 wherein R<sub>8</sub> is N.
- 28. (currently amended) The compound of claim 25 claim 24 having of the formula:

wherein  $R_{11}$  is H,  $C_5$ - $C_{18}$  alkyl,  $C_5$ - $C_{18}$  alkenyl,  $C_5$ - $C_{18}$  alkynyl, or  $C_5$ - $C_{18}$  alkoxy;  $R_3$  is  $CH_3$ ; and  $R_{29}$  is H,  $C_1$ - $C_4$  alkyl.

- 29. (previously presented) The compound of claim 28 wherein  $R_{11}$  is  $C_5$ - $C_{18}$  alkyl, or  $C_5$ - $C_{18}$  alkenyl; and  $R_{29}$  H, or  $C_1$ - $C_4$  alkyl.
- (previously presented) The compound of claim 28 wherein R<sub>11</sub> is C<sub>5</sub>-C<sub>18</sub> alkyl or C<sub>5</sub>-C<sub>18</sub>
  alkenyl; and R<sub>29</sub> is H.

# (currently amended) A pharmaceutical composition comprising a compound having of the formula:

$$R_{11}$$
 $R_{29}$ 
 $(CH_2)_m$ 
 $R_7$ 
 $R_8$ 
 $(CH_2)_y$ 
 $CR_{15}$ 
 $NH_2$ 
 $R_3$ 

wherein

$$\begin{split} R_{11} & is \ C_5 - C_{18} \ alkeyl, \ C_5 - C_{18} \ alkenyl, \ C_5 - C_{18} \ alkenyl, \ C_5 - C_{18} \ alkenyl, \ C_5 - C_{10} \ alkyl(C_5 - C_{10} \ alkoxy(C_5 - C_{10} \ alkox$$

wherein R20 is H or C1-C10 alkyl;

R<sub>29</sub> is H, halo, C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> alkenyl, C<sub>2</sub>-C<sub>12</sub> alkynyl, or C<sub>1</sub>-C<sub>12</sub> alkoxy;

R<sub>3</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)OH, or (C<sub>1</sub>-C<sub>4</sub> alkyl)NH<sub>2</sub>;

 $R_{23}$  is H, F, CO<sub>2</sub>H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)OH, or (C<sub>1</sub>-C<sub>4</sub> alkyl)NH<sub>2</sub>;

R24 is H, F or PO3H2; or

 $R_{23}$  together with  $R_{24}$  and the carbon to which they are attached form a carbonyl group;

R7 and R8 are independently O, S, CHR26, CR26, NR26, or N;

R25 is CR26;

wherein R26 is H, F or C1-C4 alkyl;

R<sub>15</sub> is

$$-X - P = \begin{bmatrix} R_{30} & R_{30} & R_{31} \\ R_{31} & R_{30} & R_{30} \\ R_{31} & R_{30} & R_{30} \end{bmatrix}$$

USSN: 10/578,216

Group Art Unit: 1626 Docket No.: 198P00944USWO

. . . . . . . . . . . . .

wherein R<sub>12</sub> is O, NH or S;

each R<sub>30</sub> is independently and each R<sub>31</sub> is independently C<sub>1</sub>-C<sub>2</sub> alkoxy,

y and m are integers independently ranging from 0 to 4; p and q are integers independently ranging from 1 to 10; or a pharmaceutically acceptable salt or tautomer thereof; and a pharmaceutically acceptable carrier.

 (currently amended) The composition of claim 31 wherein the comprising a compound has of the formula: USSN: 10/578,216 Group Art Unit: 1626

Docket No.: 198P00944USWO

Q is

$$R_{11}$$
  $Q$   $CHR_{15}$   $R_{23}$   $NH_2$ 

 $\label{eq:wherein R11 is C5-C18 alkyl, C5-C18 alkenyl, C5-C18 alkynyl, or C5-C18 alkynyl, or C5-C18 alkoxy; wherein p and q are integers independently ranging from 1 to 10; \\$ 

$$R_8$$

wherein R7 and R8 are independently O, S, CR26, CHR26, NR26, or N;

R25 is CR26; and

R<sub>26</sub> is H, F or C<sub>1</sub>-C<sub>4</sub> alkyl;

R3 is H, C1-C4 alkyl or (C1-C4 alkyl)OH;

R23 is H, F or C1-C4 alkyl; and

R<sub>15</sub> is represented by the structure

$$-x-P \xrightarrow{R_{12} \atop R_{30}} R_{30}$$

wherein R<sub>12</sub> is O or S;

 $R_{30}\, \text{and}\,\, R_{31}$  are independently  $C_1\text{-}C_2$  alkoxy,

USSN: 10/578,216 Group Art Unit: 1626

Docket No.: 198P00944USWO

or a pharmaceutically acceptable salt or tautomer thereof; and a pharmaceutically acceptable carrier.

33. (previously presented) The composition of claim 32 wherein R<sub>23</sub> is H or F; and R<sub>15</sub> is

$$-X-P < \begin{matrix} R_{30} \\ R_{31} \\ \vdots \end{matrix}$$
 wherein X is O, CH<sub>2</sub>, CHOH, CHF, CF<sub>2</sub>, or 
$$-C - .$$

- 34. (cancelled).
- (currently amended) The composition of claim 54 elaim 53 wherein X is CH<sub>2</sub>, CF<sub>2</sub> or CHF; and R<sub>30</sub> and R<sub>31</sub> are independently C<sub>1</sub>-C<sub>2</sub> alkoxy,

36. - 49. (cancelled)

#### (currently amended) A compound having of the formula:

wherein

$$\begin{split} R_{11} & is \ C_5 - C_{18} \ alkeyl, \ C_5 - C_{18} \ alkenyl, \ C_5 - C_{18} \ alkenyl, \ C_5 - C_{18} \ alkenyl, \ C_5 - C_{10} \ alkyl(C_5 - C_{10} \ alkoxy(C_5 - C_{10} \ alko$$

wherein R20 is H or C1-C10 alkyl;

R<sub>29</sub> is H, halo, C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> alkenyl, C<sub>2</sub>-C<sub>12</sub> alkynyl, or C<sub>1</sub>-C<sub>12</sub> alkoxy;

R<sub>3</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)OH, or (C<sub>1</sub>-C<sub>4</sub> alkyl)NH<sub>2</sub>;

 $R_{23} \ \mathrm{is} \ H, F, CO_2H, OH, C_1\text{-}C_6 \ alkyl, (C_1\text{-}C_4 \ alkyl)OH, or (C_1\text{-}C_4 \ alkyl)NH_2;$ 

 $R_{24}$  is H, F,  $C_1$ - $C_4$  alkyl, or  $PO_3H_2$ ; or

 $R_{23}$  together with  $R_{24}$  and the carbon to which they are attached form a carbonyl group;

R7 and R8 are independently O, S, CHR26, CR26, NR26, or N;

R25 is CR26;

wherein R26 is H, F or C1-C4 alkyl;

R<sub>15</sub> is

$$-X - P \xrightarrow{R_{12}} R_{30} \quad \text{or} \quad -C - OH \\ R_{31} \qquad P \\ R_{31} \qquad R_{30} \qquad R_{30}$$

wherein R<sub>12</sub> is O, NH or S;

X is O, NH, S, CH<sub>2</sub>, CHOH, CHF, CF<sub>2</sub>, or  $-\frac{II}{C}$ ; and each R<sub>30</sub> is independently and each R<sub>31</sub> is independently C<sub>1</sub>-C<sub>2</sub> alkoxy,

y and m are integers independently ranging from 0 to 4; p and q are integers independently ranging from 1 to 10; or a pharmaceutically acceptable salt or tautomer thereof.


# 51. (currently amended) The compound of claim 50 having of the formula

$$R_{29}$$
 $Q$ 
 $CH-R_{15}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 

wherein  $R_{11}$  is  $C_5$ - $C_{18}$  alkyl,  $C_5$ - $C_{18}$  alkenyl,  $C_5$ - $C_{18}$  alkynyl, or  $C_5$ - $C_{18}$  alkoxy;  $R_{15}$  is

$$-x-P < R_{30} R_{31}$$

wherein X is O, CH<sub>2</sub>, CHOH, CHF, CF<sub>2</sub>, or  $\stackrel{\bigcirc}{-}$ C-;  $\stackrel{\bigcirc}{R_{30}}$  and  $\stackrel{\bigcirc}{R_{31}}$  are independently  $\stackrel{\bigcirc}{C_1}$ -C<sub>2</sub> alkoxy,




52. (currently amended) The compound of claim 51 having of the formula:

$$\begin{array}{c|c} R_{29} & R_{23} \\ \hline R_{11} & R_{3} & NH_{2} \end{array}$$

 $R_{12}$  is O; and X is O, CH<sub>2</sub>, CHOH, CHF, CF<sub>2</sub>, and  $C^-$ .

- 53. (previously presented) The compound of claim 23 wherein X is O,  $CH_2$ , CHF or  $CF_2$ .
- 54. (currently amended) The composition of claim 33 wherein Q is



55. (currently amended) The composition of claim 35 wherein Q is